Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Michael Pavlides

Dr Michael Pavlides is the head of liver imaging at the Oxford Centre for Clinical Magnetic Resonance Research (OCMR), and an honorary consultant hepatologist and gastroenterologist at the Oxford University Hospitals NHS Foundation Trust. He leads the hepato-biliary imaging work in the imaging theme of the Oxford NIHR Biomedical Research Centre, aiming to develop and validate quantitative imaging biomarkers of liver and biliary disease.  His work focuses on the clinical application of MRI techniques for diagnosis of liver disease and its complication like portal hypertension. His work has been published in some of the leading hepatology journals and led to the development of intellectual property.

Michael was awarded a DPhil from the University of Oxford in 2016 for his work on multiparametric MRI for the assessment of patients with chronic liver disease. He completed his medical specialty training in October 2017 and triple accredited in Gastroenterology with sub-specialty in Hepatology and General Internal Medicine. He completed a year of advanced hepatology training including an attachment to the Cambridge Liver Transplant Unit, and previously worked on the Royal Free Liver Transplant Unit in 2006. He completed his undergraduate medical training in 2004 at University College London. During his medical training he successfully completed a BSc degree in “Medical Science and Neuroscience” and was awarded 3 prizes/scholarships. 

Michael now leads the imaging work packages in the DeLIVER consortia, aiming to i) validate imaging biomarkers for the early detection of liver cancer and ii) characterise the features of the cirrhotic linked that may predict HCC transformation.